pretickt

Is MRNA a good stock to buy?

Moderna, Inc. · end-of-day data as of Nov 13, 2026

Moderna
MRNA · $90.38B
$223.37-3.4%
Nov 13, 2026 · close
$100$200SepOctNov9:3016:003 months +254.8%Nov 13 · close
▲ 3
  • Trendbullish
  • MAs3 of 4
  • Sector▲ +15.9%
Neutral
  • Earnings in91d
  • RSI50
  • Support-9.9%
  • Off 52w high-20.5%
  • Volume0.5x
  • Bollingerlower half
  • ConsensusHold · 24
  • 52w range$22–$281
  • ATR+8.9%
  • Off ATH-55.1%
  • MA20×50↓ in ~35d
▼ 5
  • PT$122.40 -45.2%
  • FCF yield-2.2%
  • Insiders-$33.88M
  • News
  • MACD-2.22

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Moderna a good stock to buy?

Moderna is strong on 2 of the 5 questions about the business; weak on demand, advantage and economics. With a loss over the last 12 months, Moderna has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand shrinking
  2. Advantage easy to copy
  3. Economics losing money
  4. Execution delivers
  5. Fragility sturdy
  6. Price above its peers
DemandDo people want more of what it sells?shrinking

MRNA sales growth revenue growth

-53%a year, for the last 3 years

Moderna's sales fell 53% a year for 3 years, to $1.94B in fiscal 2025.

MRNA competitors

pretickt analysis+14%its sales in 12 months, on a year before

Moderna's sales grew 14% in the 12 months to Sep 30, 2026, faster than Vertex (+11%), slower than Alnylam (+56%), Incyte (+25%) and Regeneron (+19%).

MRNA sales by business revenue by segment

93%of its sales from COVID

COVID brought Moderna 93% of its sales in fiscal 2025; Stand-ready manufacturing revenue 4%.

Advantage moatIs it hard to copy?easy to copy

MRNA return on capital ROIC

pretickt analysis-30%earned before tax on the money invested in it

Moderna earned -30% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Alnylam 31%, Incyte 29%, Vertex 20% and Regeneron 15%.

MRNA margin on each sale gross margin

28%left after making the product

Moderna kept 28% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 86%.

EconomicsDoes it make good money?losing money

MRNA margin after costs profit margin

-116%of sales left after running the business

Moderna's operating margin was -116% in the 12 months to Sep 30, 2026, against 50% in fiscal 2022.

ExecutionDoes it deliver what it promises?delivers

MRNA earnings vs estimates

6 of 6quarters above the analysts' estimate

Moderna beat the analysts' profit estimate in all 6 quarters, the latest on Jul 31, 2026; 2 quarters with one-time gains or charges are left out.

MRNA insider selling

-$81.65Msold, net, by its executives in 12 months

Moderna's executives and directors sold a net $81.65M of shares in the 12 months to Nov 13, 2026; none bought.

MRNA number of employees

-19%fewer people in a year

Moderna had 4,700 employees at the end of fiscal 2025, 19% fewer than a year before.

MRNA CEO pay

$19.93Mfor fiscal 2025, 69% of it in stock and options

Moderna paid its CEO $19.93M for fiscal 2025, 69% of it in stock and options.

Fragility risksCould something break it?sturdy

MRNA financial health Altman Z-score

9.0Altman Z-score, safe above 3

Moderna's Altman Z-score is 9.0 (Nov 13, 2026), above 3, where the safe zone starts.

MRNA quality checks Piotroski score

4 of 9checks passed

Moderna passes 4 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on profit, cash from operations, long-term debt, the current ratio and new shares.

MRNA biggest customers

39%of sales from its 3 biggest customers

FFF Enterprises, Public Works and Government Services Canada and Cardinal Health made 39% of Moderna's sales in fiscal 2025.

Price valuationIs the price reasonable?above its peers

MRNA price vs profit P/E ratio

—it lost money in 12 months: no P/E

Moderna has no P/E ratio: it lost money over the 12 months to Sep 30, 2026.

MRNA price vs assets price to book

13.2×times what its assets are worth on paper

Moderna trades at 13.2 times its book value (Nov 13, 2026); its competitors' median is 5.3.

MRNA analysts' target price target

-45%to their average target

Analysts' average price target for Moderna is $122, 45% below the Nov 13, 2026 close of $223.37.

MRNA analyst ratings, 90 days

pretickt analysis
  • Wolfe Researchupgrade
  • Argus Researchupgrade
  • Rothschild & Codowngrade
  • Citigroupdowngrade
  • William Blairdowngrade
2 up, 3 downratings raised and cut

In the 90 days to Nov 13, 2026, Wolfe Research and Argus Research upgraded Moderna; Rothschild & Co, Citigroup and William Blair downgraded it.

What is Moderna's P/E ratio?

Moderna has no P/E ratio: it lost money over the 12 months to Sep 30, 2026. Moderna trades at 13.2 times its book value (Nov 13, 2026); its competitors' median is 5.3.

Who are Moderna's biggest competitors?

pretickt compares Moderna with Regeneron, Vertex, Incyte and Alnylam. Moderna's sales grew 14% in the 12 months to Sep 30, 2026, faster than Vertex (+11%), slower than Alnylam (+56%), Incyte (+25%) and Regeneron (+19%).

Is Moderna profitable?

Moderna's operating margin was -116% in the 12 months to Sep 30, 2026, against 50% in fiscal 2022.

Are insiders selling Moderna stock?

Moderna's executives and directors sold a net $81.65M of shares in the 12 months to Nov 13, 2026; none bought.

How does Moderna make money?

COVID brought Moderna 93% of its sales in fiscal 2025; Stand-ready manufacturing revenue 4%.

How many employees does Moderna have?

Moderna had 4,700 employees at the end of fiscal 2025, 19% fewer than a year before.

Who are Moderna's biggest customers?

FFF Enterprises, Public Works and Government Services Canada and Cardinal Health made 39% of Moderna's sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.